4.6 Review

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

Journal

VIRUSES-BASEL
Volume 2, Issue 6, Pages 1279-1305

Publisher

MDPI
DOI: 10.3390/v2061279

Keywords

antiviral therapy; HBV therapy; nucleoside analogs; viral hepatitis

Categories

Funding

  1. VIRGIL European Network of Excellence on Antiviral Drug Resistance [LSHM-CT-2004-503359]
  2. FWO [G.0267.04]

Ask authors/readers for more resources

While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available